Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 20/20 | 0.91 |
| ▸ | PRKAB2 | O43741 | 16/20 | 0.84 |
| ▸ | PRKAG1 | P54619 | 16/20 | 0.84 |
| ▸ | PRKAA1 | Q13131 | 16/20 | 0.84 |
| ▸ | PRKAG3 | Q9UGI9 | 16/20 | 0.84 |
| ▸ | PRKAG2 | Q9UGJ0 | 16/20 | 0.84 |
| ▸ | PRKAB1 | Q9Y478 | 16/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518208 | 0.95 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518922 | 0.94 | PRKAA2 (0.98) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL12199998 | 0.92 | PRKAA2 (0.90) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL18013666 | 0.91 | PRKAA2 (0.93) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518421 | 0.91 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518940 | 0.91 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518544 | 0.91 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL517980 | 0.90 | PRKAA2 (0.90) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518515 | 0.90 | PRKAA2 (0.90) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 | |
| SCHEMBL518212 | 0.90 | PRKAA2 (1.00) | PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266856-B2 | AMPK—activating heterocyclic compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | PRKAA2 7/4885PRKAB2 5/4885PRKAG1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.